Aclarion, Inc. $ACON
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Services-Medical Laboratories
- Headquarters
- Broomfield, CO
- Fiscal year end
- December 31
- Shares outstanding
- 2,882,371 [10-Q 2026-08-06]
What the company doesAI summary of filing
Aclarion is a healthcare technology company that develops software to analyze intervertebral discs using Magnetic Resonance Spectroscopy (MRS) to help identify which discs are causing low back pain. The company's primary product, NOCISCAN, is cloud-based software that post-processes MRS imaging data to provide physicians with information about disc chemical composition and whether discs are consistent with generating pain, intended to assist in surgical decision-making for chronic discogenic low back pain patients. The company is currently in the early revenue-generating stage, with limited sales to date, and has published clinical studies showing improved surgical outcomes when discs identified as painful by NOCISCAN are included in surgical treatment. Aclarion makes money through licensing its software to MRI imaging centers and selling analysis services to physicians, supported by recently obtained CPT codes and participation in NIH research programs. [10-K 2026-03-18]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $46.3K | −$5.60M | −$5.30M | $16.29M | [10-Q 2026-08-06] |
| FY ended Dec 2025 | $75.7K | −$7.23M | −$7.16M | $12.02M | [10-K 2026-03-18] |
| FY ended Dec 2024 | $45.7K | −$6.99M | −$5.27M | $453.7K | [10-K 2026-03-18] |
- Quarterly cash burn
- −$2.65M
- Cash runway Estimate
- ~18.4 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-14 | 10,431,159 | [10-Q 2024-11-14] |
| 2025-04-09 | 582,371 | [10-K 2025-04-09] |
| 2025-05-15 | 582,371 | [10-Q 2025-05-15] |
| 2025-08-14 | 582,371 | [10-Q 2025-08-14] |
| 2025-11-10 | 671,371 | [10-Q 2025-11-12] |
| 2026-03-17 | 2,282,371 | [10-K 2026-03-18] |
| 2026-05-11 | 2,462,250 | [10-Q 2026-05-13] |
| 2026-08-04 | 2,882,371 | [10-Q 2026-08-06] |
- Shelf registration
- S-3 filed 2025-04-25; declared effective 2025-05-05 [S-3 2025-04-25]
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2024-10-11. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2024-10-11 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2024-10-11] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-17 | Williams Amanda M | buy | 5,857 | $2.73 | [4 2026-08-19] |
| 2026-08-14 | Gould Gregory A | buy | 10,000 | $2.45 | [4 2026-08-18] |
| 2026-08-13 | Bond Ryan | buy | 21,122 | $2.37 | [4 2026-08-17] |
| 2026-08-13 | Wesemann William | buy | 2,150 | $2.34 | [4 2026-08-17] |
| 2026-08-13 | Neal David K | buy | 7,500 | $2.40 | [4 2026-08-17] |
| 2026-08-13 | Ness Brent | buy | 5,234 | $2.31 | [4 2026-08-17] |
| 2026-06-11 | Bond Ryan | grant | 55,000 | — | [4 2026-06-12] |
| 2026-06-11 | Sequira Amanda Mae | grant | 20,000 | — | [4 2026-06-12] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-06 | 10-Q | Quarterly report |
| 2026-06-04 | 8-K | Shareholder vote results |
| 2026-05-13 | 10-Q | Quarterly report |
| 2026-04-27 | DEF 14A | Proxy statement |
| 2026-04-22 | 8-K | Other events |
| 2026-04-03 | PRE 14A | Proxy statement |
| 2026-03-25 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-03-19 | 8-K | Material agreement entered; Change to security holder rights; Charter, bylaws or fiscal year change |
| 2026-03-18 | 10-K | Annual report |
| 2026-01-13 | 8-K | Regulation FD disclosure |
| 2026-01-09 | 8-K | Material agreement entered |
| 2026-01-09 | 424B5 | Prospectus or prospectus supplement |
Alerts for $ACON
Email me when Aclarion, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.